Phase 1 Trial for SYS6043: A New Antibody-Drug Conjugate Targeting B7-H3

SYS6043 is a new type of antibody-drug conjugate, or ADC. It zeroes in on B7-H3, a protein that is expresse by advanced tumors but almost not at all on healthy cells. The antibody part sticks to B7-H3, gets pulled inside the cancer cell, and releases a topoisomerase I inhibitor that breaks the cell’s DNA and kills it.

B7-H3 is relatively rare in early prostate cancer but jumps to 20-80% in spread-out cases, particularly bone mets and fast-growing types. These tumors use B7-H3 to hide from the immune system and grow via paths like PI3K/AKT. Lab tests showed SYS6043 wiping out resistant prostate cells which can often develop after taxanes or PARP inhibitors.

.The Phase 1 trial tests safety and dosing first, then specific groups including mCRPC with limited bone-only disease. It checks side effects, blood levels of the drug, tumor shrinkage, and B7-H3 markers in adults fit enough for treatment.

Clinical trial.